Yan-yan Shen

发表

G protein-coupled receptor GPR160 is associated with apoptosis and cell cycle arrest of prostate cancer cells

Yi Chen, T. Bártfai, Jian Ding, 2016, Oncotarget.

Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy.

Yun Tang, Yi Chen, Z. Miao, 2017, European journal of medicinal chemistry.

Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models

Yi Chen, Jian Ding, M. Geng, 2019, Journal of Experimental & Clinical Cancer Research.

G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin

Yi Chen, Jian Ding, M. Geng, 2017, Nature Communications.

Regulation of CCL2 by EZH2 affects tumor-associated macrophages polarization and infiltration in breast cancer

Yan-fen Fang, Yi Chen, Minfang Song, 2022, Cell Death & Disease.

G9a stimulates CRC growth by inducing p53 Lys373 dimethylation-dependent activation of Plk1

Yi Chen, Jian Ding, Yan-yan Shen, 2018, Theranostics.

Identification of compound D2923 as a novel anti-tumor agent targeting CSF1R

Yi Chen, Jian Ding, Lin-jiang Tong, 2018, Acta Pharmacologica Sinica.

Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.

Na Ye, Yi Chen, Z. Miao, 2017, Cancer letters.

AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR

Yi Chen, Jian Ding, Lin-jiang Tong, 2012, Journal of cellular and molecular medicine.

Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance

Yi Chen, Z. Miao, Jian Ding, 2023, EMBO molecular medicine.

Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models

Yi Chen, Jian Ding, M. Geng, 2019, Journal of experimental & clinical cancer research : CR.

c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors

Min Huang, Yi Chen, Jian Ding, 2016, Clinical Cancer Research.

Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors

Yi Chen, Z. Miao, Jian Ding, 2017, Acta Pharmacologica Sinica.

ASK120067 potently suppresses B-cell or T-cell malignancies in vitro and in vivo by inhibiting BTK and ITK

Yi Chen, Jian Ding, Lin-jiang Tong, 2022, Frontiers in Pharmacology.

SLC1A1-mediated cellular and mitochondrial influx of R-2-hydroxyglutarate in vascular endothelial cells promotes tumor angiogenesis in IDH1-mutant solid tumors

Leping Li, Min Huang, Lin-jiang Tong, 2022, Cell Research.

Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors

Min Huang, Yi Chen, Jian Ding, 2018, Cell.

Histone deacetylase inhibitors promote breast cancer metastasis by elevating NEDD9 expression

Yi Chen, Jian Ding, Yan-fen Fang, 2023, Signal Transduction and Targeted Therapy.

SOMCL-863, a novel, selective and orally bioavailable small-molecule c-Met inhibitor, exhibits antitumor activity both in vitro and in vivo.

Min Huang, Jian Ding, M. Geng, 2014, Cancer letters.

Marine-derived chromopeptide A, a novel class I HDAC inhibitor, suppresses human prostate cancer cell proliferation and migration

M. Geng, Yu-Chih Liu, Min-min Zhang, 2017, Acta Pharmacologica Sinica.

c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers.

Min Huang, Yi Chen, Jian Ding, 2015, Cancer research.

Structural Optimization of Fibroblast Growth Factor Receptor Inhibitors for Treating Solid Tumors.

Xutong Li, M. Geng, Hong Liu, 2023, Journal of medicinal chemistry.

SOMCL-085, a novel multi-targeted FGFR inhibitor, displays potent anticancer activity in FGFR-addicted human cancer models

Wei-ren Liu, Yinghong Shi, Zhen-Bin Ding, 2017, Acta Pharmacologica Sinica.

Discovery of pyrrolo[2,3-d]pyrimidine derivatives as potent Axl inhibitors: Design, synthesis and biological evaluation.

M. Geng, Yin-chun Ji, W. Duan, 2021, European journal of medicinal chemistry.

Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution

M. Wang, Yi Chen, Z. Miao, 2016, Oncotarget.

HSP90 inhibitor AUY922 abrogates up‐regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer

Yi Chen, Ling-hua Meng, Jian Ding, 2014, International journal of cancer.

Marine-derived chromopeptide A, a novel class I HDAC inhibitor, suppresses human prostate cancer cell proliferation and migration

M. Geng, Yu-Chih Liu, Hongchun Liu, 2017, Acta Pharmacologica Sinica.

Simm530, a novel and highly selective c-Met inhibitor, blocks c-Met-stimulated signaling and neoplastic activities

Jian Ding, M. Geng, Wei-ren Liu, 2016, Oncotarget.

Intact regulation of G1/S transition renders esophageal squamous cell carcinoma sensitive to PI3Kα inhibitors

Yi Chen, Lan Xu, Linghua Meng, 2023, Signal Transduction and Targeted Therapy.

SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer

M. Geng, Xuchao Zhang, Zuoquan Xie, 2023, Signal transduction and targeted therapy.

Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models

Yi Chen, Jian Ding, M. Geng, 2017, Molecular Cancer Therapeutics.

Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance

Yi Chen, Jian Ding, Lin-jiang Tong, 2020, Molecular Cancer.

Molecularly precise self-assembly of theranostic nanoprobes within a single-molecular framework for in vivo tracking of tumor-specific chemotherapy† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c8sc01069b

H. Tian, Zhiqian Guo, Weihong Zhu, 2018, Chemical science.

Identification of compound D2923 as a novel anti-tumor agent targeting CSF1R

Yi Chen, Jian Ding, Lin-jiang Tong, 2018, Acta Pharmacologica Sinica.

Tanshinone-1 induces tumor cell killing, enhanced by inhibition of secondary activation of signaling networks

Y. Chen, Z. Miao, Jian Ding, 2013, Cell Death and Disease.

Identification of [1,2,4]Triazolo[4,3-a]pyrazine PARP1 inhibitors with overcome acquired resistance activities.

Yi Chen, Z. Miao, Pingyuan Wang, 2023, European journal of medicinal chemistry.

Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance

Yi Chen, Jian Ding, Lin-jiang Tong, 2020, Molecular Cancer.

The B-RafV600E inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury

Z. Miao, Jian Ding, B. Xiong, 2014, Cell Death and Disease.

Simm530, a novel and highly selective c-Met inhibitor, blocks c-Met-stimulated signaling and neoplastic activities

Jian Ding, M. Geng, Yin-chun Ji, 2016, Oncotarget.

Preclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood–brain barrier and exhibits potent activity against glioblastoma

Lin-jiang Tong, Hua Xie, Yan-yan Shen, 2023, Acta pharmaceutica Sinica. B.

Molecularly precise self-assembly of theranostic nanoprobes within a single-molecular framework for in vivo tracking of tumor-specific chemotherapy

H. Tian, Zhiqian Guo, Weihong Zhu, 2018, Chemical science.

c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers.

Min Huang, Yi Chen, Jian Ding, 2015, Cancer research.

Histone deacetylase inhibitors promote breast cancer metastasis by elevating NEDD9 expression

Yi Chen, Jian Ding, Yan-fen Fang, 2023, Signal Transduction and Targeted Therapy.